• Latest
  • Trending
SMEs and the role of Fintech during the Covid-19

After the COVID blow, climate change pushes Lyme disease in France’s Valneva’s attention

After China central bank vows to crack crypto trade, Bitcoin slips

A glimpse of Cryptoverse DEX, and a brief accounting

FTX invested $300 million in Bahamas property as “personal fiefdom”

FTX invested $300 million in Bahamas property as “personal fiefdom”

Ant group sees fine from China over $1 bln, suggesting overhaul is almost done

Ant group sees fine from China over $1 bln, suggesting overhaul is almost done

Africa calls for climate finance tracker

COP27 agreement achieves a milestone on “damage and loss,” but not more

Budweiser World Cup advertising is limited by Qatar’s liquor ban; not destroyed

Budweiser World Cup advertising is limited by Qatar’s liquor ban; not destroyed

UK trade policy : A comprehensive strategy for a new beginning

British insurers serve as a trial run for the post-Brexit “unshackling”

STARLINK satellite internet service gets 500,000 preorders, Musk says

Musk claims he was engaged in revitalizing Tesla while upholding his $56 bln package

In a long-awaited trial, Roche’s Alzheimer’s medicine falls short of its objective

In a long-awaited trial, Roche’s Alzheimer’s medicine falls short of its objective

Electric vehicle manufacturers struggle financially—struck by exorbitant prices

Electric vehicle manufacturers struggle financially—struck by exorbitant prices

After China central bank vows to crack crypto trade, Bitcoin slips

Bahamas investigators are looking into the FTX collapse

Volatility is most essential for crypto ecosystem

Morning Bid: Crypto a disaster, Congress looking different ways

Binance registers with Italy’s regulator amid plans to expand in Europe

Cryptocurrencies drop after FTX-Binance dispute worries investors

Global Business Review Magazine
Wednesday, February 8, 2023
Nominate Here
  • Home
  • Banking
  • Finance
  • Technology
  • FinTech
  • Business
  • Videos
  • Events
  • Awards
  • Magazine
No Result
View All Result
Global Business Review Magazine
No Result
View All Result

After the COVID blow, climate change pushes Lyme disease in France’s Valneva’s attention

SMEs and the role of Fintech during the Covid-19

Drugmaker Valneva (VLS.PA) is placing a large wager on a vaccine as it looks past dismal sales of its COVID shot as increased cases of tick-borne and deadly Lyme disease are being caused by climate change.

Although Valneva received regulatory approval from the European Union and the British government, both organisations terminated contracts totalling greater than a billion dollars, erasing approximately 40% of the worth of Valneva’s stock value over the previous six months.

YOU MAY ALSO LIKE

COP27 agreement achieves a milestone on “damage and loss,” but not more

Budweiser World Cup advertising is limited by Qatar’s liquor ban; not destroyed

Based on more recent messenger RNA (mRNA) new tech, which teaches cells how to manufacture a protein that would activate an immune response, the French company promoted its COVID-19 vaccine as a conventional option for those who had refused doses.

There are no well-established competitors either for Lyme disease or Chikungunya, in contrast to the strong battle with large worldwide drugmakers like Pfizer, Moderna, and AstraZeneca to bring out medicines to combat the coronavirus pandemic.

Based on the Disease Prevention & Control, under the European Centre, diseases conveyed by so-called vectors like ticks and mosquitoes are on the rise as climate change causes longer summers and warmer winters in several parts of the planet, including North America and Europe.

The incidence of disease-causing vectors has significantly increased, according to Thomas Lingelbach, chief executive of Valneva. He admitted in an interview that global warming is undoubtedly a significant factor, if not the primary one.

The business, situated in Saint-Herblain, southwest France, is getting ready to launch a delayed human test for its prototype Lyme disease vaccine and will shortly submit its Chikungunya vaccine for U.S. approval following successful late-stage research.

In the upcoming weeks, the Lyme disease vaccination study will begin. It will involve at least 5,000 adults.

The germs that cause Lyme disease is often carried by ticks the size of poppy seeds. Some people discover they have had the disease after the fact, even though the majority of bites do not result in infection & not everyone affected gets the recognisable rash.

But at this time, normal antibiotic therapy may no longer be effective, and some patients may continue to experience dangerous side effects, such as brain inflammation if left untreated.

Chikungunya is primarily disseminated in the developing world, which includes Africa, Asia, and the Indian subcontinent, by the sting of an infected mosquito.

The viral illness is characterised by severe muscle spasms that can linger for months or years, even though it is rarely fatal.

If authorised, Valneva plans to market its Chikungunya vaccine to both populations in rich nations and those in low- or middle nations as a travel vaccination. Samir Devani, an analyst at Rx Securities, predicts peak revenues of $250 million.

Given the expanding tick population, increased infection rates, and occurrence of long-term consequences, Valenva anticipates that the Lyme disease vaccine, designated as VLA15, will produce global annual sales of $1 billion if it is effective.

For Valneva, which brought in 350 million euros in sales last year, that might prove to be a game-changer.

Monkeypox outbreaks recently outside of Africa, wherein it is endemic, and the 1918 pandemic have rekindled interest in infectious illness vaccines among pharmaceutical companies and investors.

David Pinniger, Polar Capital’s Healthcare Fund Manager, revealed that endemic diseases that are either recurrent or susceptible to acute periodic outbreaks are a significant public health concern for poor countries and present a “big potential” for vaccine manufacturers.

Individuals who reside in rural settings and other areas where ticks are common may benefit from VLA15, according to Lingelbach.

Instead of only targeting one bacterial strain as was the case with LYMErix, VLA15 is made to combat many bacterial strains. Lyme disease is also more understood scientifically, and celebrities like Justin Bieber & Amy Schumer have taken their battles with it public.

Tags: businessCovidRecovery
ShareTweetShare

Search

No Result
View All Result

Recent News

After China central bank vows to crack crypto trade, Bitcoin slips

A glimpse of Cryptoverse DEX, and a brief accounting

FTX invested $300 million in Bahamas property as “personal fiefdom”

FTX invested $300 million in Bahamas property as “personal fiefdom”

Ant group sees fine from China over $1 bln, suggesting overhaul is almost done

Ant group sees fine from China over $1 bln, suggesting overhaul is almost done

Africa calls for climate finance tracker

COP27 agreement achieves a milestone on “damage and loss,” but not more

Budweiser World Cup advertising is limited by Qatar’s liquor ban; not destroyed

Budweiser World Cup advertising is limited by Qatar’s liquor ban; not destroyed

UK trade policy : A comprehensive strategy for a new beginning

British insurers serve as a trial run for the post-Brexit “unshackling”

Global Business Review Magazine

Global Business Review is a online print magazine focusing on the updates and information about on emerging markets, Finance, Banking, Technology. Global Business Review provides news, features, analysis, commentary, and interviews from industry across the globe.

Recent News

  • A glimpse of Cryptoverse DEX, and a brief accounting
  • FTX invested $300 million in Bahamas property as “personal fiefdom”
  • Ant group sees fine from China over $1 bln, suggesting overhaul is almost done
  • COP27 agreement achieves a milestone on “damage and loss,” but not more
  • Budweiser World Cup advertising is limited by Qatar’s liquor ban; not destroyed

Categories

  • Banking
  • Business
  • Events
  • Finance
  • FinTech
  • Tech
  • Videos
  • About
  • Nominate
  • Privacy & Policy

© 2022 Global Business Review Magazine - All Rights Reserved.

No Result
View All Result
  • Home
  • Banking
  • Finance
  • Technology
  • FinTech
  • Business
  • Videos
  • Events
  • Awards
  • Magazine

© 2022 Global Business Review Magazine - All Rights Reserved.

Go to mobile version